Jasper Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Jasper Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.7 times its market value (net cash). Higher than 94% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-232.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 90% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-62.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 77% of Healthcare companies in United States.
Cash Cushion Ratio
1.7× cashCash, after subtracting all debt, is 1.7 times its market value (net cash).
Higher than 94% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Jasper Therapeutics, Inc. made a loss over the last year. Jasper Therapeutics, Inc. owes $0.88 for every $1 it owns. Jasper Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossJasper Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
11.67The share price is 11.67 times Jasper Therapeutics, Inc.'s book value per share, higher than 88% of Healthcare companies in United States.
Market cap
$16 MThe total market value of all of Jasper Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 83% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$1 MWhat Jasper Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.04Net worth divided by the number of shares. The share price of $0.50 is 11.7 times this, which is the P/B above.
Owes vs Owns
0.88×Jasper Therapeutics, Inc. owes $0.88 for every $1 it owns (high), higher than 82% of Healthcare companies in United States.
Dividend yield
NoneJasper Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossJasper Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashJasper Therapeutics, Inc. held $27 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Jasper Therapeutics, Inc.: $16 M ÷ $1 M (30 Jun 2026) = 11.7.
How much does Jasper Therapeutics, Inc. owe compared with what it owns?
Jasper Therapeutics, Inc. owes $0.88 for every $1 it owns (high), higher than 82% of Healthcare companies in United States.
Does Jasper Therapeutics, Inc. pay a dividend?
No. Jasper Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.